Andrew Benjamin Nixon, PhD

Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Associate Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • Ph.D., Wake Forest University, 1997

Publications

Strickler, John H., Christel N. Rushing, Donna Niedzwiecki, Abigail McLeod, Ivy Altomare, Hope E. Uronis, S David Hsu, et al. “A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer..” Bmc Cancer 19, no. 1 (November 1, 2019). https://doi.org/10.1186/s12885-019-6234-8.

PMID
31675952
Full Text

George, Daniel J., Susan Halabi, Patrick Healy, Ian Barak, Carolyn Winters, Monika Anand, Rhonda Wilder, et al. “Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer..” Prostate 79, no. 15 (November 2019): 1752–61. https://doi.org/10.1002/pros.23899.

PMID
31497882
Full Text

Corradetti, Michael N., Jordan A. Torok, Ace J. Hatch, Eric P. Xanthopoulos, Kyle Lafata, Corbin Jacobs, Christel Rushing, et al. “Dynamic Changes in Circulating Tumor DNA During Chemoradiation for Locally Advanced Lung Cancer..” Adv Radiat Oncol 4, no. 4 (October 2019): 748–52. https://doi.org/10.1016/j.adro.2019.05.004.

PMID
31673668
Full Text

Clarke, Jeffrey Melson, Gerard C. Blobe, John H. Strickler, Hope Elizabeth Uronis, S Yousuf Zafar, Michael Morse, Evan Dropkin, et al. “A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)..” Cancer Chemother Pharmacol 84, no. 4 (October 2019): 909–17. https://doi.org/10.1007/s00280-019-03916-0.

PMID
31444620
Full Text

Reed, Christopher Robert, Christopher Cameron McCoy, Uttara Nag, Andrew B. Nixon, James Otto, Jeffrey Harold Lawson, Andrew J. Lodge, Joseph W. Turek, and Elisabeth Tomlinson Tracy. “Proteomic Analysis of Infants Undergoing Cardiopulmonary Bypass Using Contemporary Ontological Tools..” J Surg Res 246 (September 25, 2019): 83–92. https://doi.org/10.1016/j.jss.2019.08.019.

PMID
31562990
Full Text

Sharma, Mayur, Cathy Schilero, David M. Peereboom, Brian P. Hobbs, Paul Elson, Glen H. J. Stevens, Keith McCrae, Andrew B. Nixon, and Manmeet S. Ahluwalia. “Phase II study of Dovitinib in recurrent glioblastoma..” J Neurooncol 144, no. 2 (September 2019): 359–68. https://doi.org/10.1007/s11060-019-03236-6.

PMID
31292802
Full Text

Innocenti, Federico, Chen Jiang, Alexander B. Sibley, Stefanie Denning, Amy S. Etheridge, Dorothy Watson, Donna Niedzwiecki, et al. “An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance)..” Pharmacogenet Genomics 29, no. 6 (August 2019): 123–31. https://doi.org/10.1097/FPC.0000000000000375.

PMID
30889042
Full Text

Gbenedio, Oghenekevwe M., Caroline Bonnans, Delphine Grun, Chih-Yang Wang, Ace J. Hatch, Michelle R. Mahoney, David Barras, et al. “RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer..” Jci Insight 5 (June 25, 2019). https://doi.org/10.1172/jci.insight.127552.

PMID
31237864
Full Text

Lin, Jiaxing, Alexander Sibley, Ivo Shterev, Andrew Nixon, Federico Innocenti, Cliburn Chan, and Kouros Owzar. “fastJT: An R package for robust and efficient feature selection for machine learning and genome-wide association studies..” Bmc Bioinformatics 20, no. 1 (June 13, 2019). https://doi.org/10.1186/s12859-019-2869-3.

PMID
31195980
Full Text

Kelly, Francine L., Kaitlyn E. Weinberg, Andrew E. Nagler, Andrew B. Nixon, Mark D. Star, Jamie L. Todd, David M. Brass, and Scott M. Palmer. “EGFR-Dependent IL8 Production by Airway Epithelial Cells After Exposure to the Food Flavoring Chemical 2,3-Butanedione..” Toxicol Sci 169, no. 2 (June 1, 2019): 534–42. https://doi.org/10.1093/toxsci/kfz066.

PMID
30851105
Full Text

Pages